Table 3 Treatment regimens of MM patients (n = 73).

From: Cytogenetic risk stratification combined with minimal residual disease status influences the therapeutic outcome and prognosis of multiple myelomas

Treatment regimens (n, %)

SR group

(n = 33)

HR group

(n = 40)

χ2

P value

Induction regimen, n (%)

  

1.378

0.516

PI

19 (57.6)

23 (57.5)

  

PI + IMiD

10 (30.3)

15 (37.5)

  

PI + IMiD + anti-CD38

4 (12.1)

2 (5.0)

  

Stem cell transplant

8 (24.2)

8 (20.0)

0.190

0.663

  1. MM, multiple myeloma; SR, standard risk; HR, high risk; PI, proteasome inhibitor; IMiD, immunomodulatory drug.
Back to article page